Giant cell arteritis (GCA), also known as Horton's arteritis, is a serious inflammatory disease that primarily affects large and medium-sized arteries, including the carotid and temporal arteries. Most often seen in older adults, the disease involves inflammation of the vessel walls, which can lead to narrowing or even occlusion. This increases the risk of serious complications such as stroke and vision loss. The disease is usually preceded by malaise, including fatigue, fever, weight loss, and night sweats, making it difficult to diagnose in a timely manner.
History of the disease and interesting historical facts
Giant cell arteritis was first described in the early 20th century, but its symptoms and pathogenesis had been observed earlier. In 1932, German ophthalmologist Frederick Ladwig recorded cases of temporal artery occlusion, which became the basis for further study of this syndrome. Interestingly, in 1958, the first successful operation to perform a continuous biopsy of the temporal artery was performed, which became a breakthrough in the rapid diagnosis of GCA.
Since the discovery of the disease, significant efforts have been made to understand its pathogenesis. In the 2000s, modern imaging techniques such as ultrasound and computed tomography have improved the diagnosis of GCA and helped to understand its molecular mechanisms.
Epidemiology
According to global studies, the epidemiology of giant cell arteritis varies by region. Overall, the prevalence of GCA ranges from 1.3 to 3.5 cases per 1,000 people among people over 50 years of age. In the United States, it has also been recorded that women suffer from this disease three times more often than men. According to statistics, the peak incidence is observed at the age of 70–80 years, and the risk of developing GCA increases with age.
Recent studies in Europe and North America have also suggested that the increase in GCA cases over the past two decades may be due to increased life expectancy and improved diagnostics, allowing more cases to be detected at earlier stages.
Genetic predisposition to this disease
Genetic predisposition plays an important role in the development of giant cell arteritis. Studies have shown that certain genes and their mutations can significantly increase the risk of developing the disease. In particular, a connection has been established between GCA and genes associated with inflammatory processes, especially with genes encoding genetic markers of human leukocyte antigen (HLA). Mutations in these genes increase the predisposition to the development of autoimmune reactions, which, in turn, can lead to inflammation of the vascular wall.
When markers such as HLA-DRB1 and HLA-DQB1 are studied, a high frequency of their occurrence is observed among patients with GCA. Thus, the genetic component is a significant risk factor that may additionally interact with environmental and other factors to contribute to the development of the disease.
Risk factors for the development of this disease
Risk factors for giant cell arteritis can be divided into several groups:
- Environmental factors: exposure to chemicals such as sulfur and heavy metals.
- Inflammatory factors: presence of inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus.
- Age and gender factors: Women have a significantly higher risk of the disease, especially at age 50 and older.
- Ethnic factors: Research shows that people of Scandinavian and Northern European descent have a higher risk of developing GCA.
Each of these factors may have different effects on your likelihood of developing giant cell arteritis and the long-term health consequences of the disease.
Diagnosis of this disease
Diagnosis of giant cell arteritis is based on a comprehensive approach, which includes:
- Main symptoms: The most characteristic symptom is a headache localized in the temporal region. The pain may be pulsating and accompanied by increased skin sensitivity and chewing claustrophobia. Other symptoms may include fatigue, fever, and weight loss.
- Laboratory tests: increased levels of ESR (erythrocyte sedimentation rate) and C-reactive protein confirm the presence of an inflammatory process in the body.
- Radiological tests: Ultrasound and magnetic resonance imaging can help visualize affected arteries and assess the degree of inflammation.
- Other diagnostic tests: temporal artery biopsy is the “gold standard” for confirming the diagnosis of GCA.
- Differential diagnosis: it is necessary to exclude other causes of headache, such as migraine, thrombophlebitis and other vascular diseases.
Early diagnosis is critical to prevent complications such as vision loss.
Treatment
Treatment of giant cell arteritis includes a multifaceted approach. The general treatment plan aims to reduce inflammation and prevent complications, especially blindness:
- General treatment: Early administration of anti-inflammatory drugs can significantly improve the patient's condition. An important role in global therapy is played by adherence to the regimen, stress management and restoration of adequate nutrition.
- Pharmacological treatment: Corticosteroids such as prednisone are the mainstay of treatment for GCA. In initial doses, they provide rapid relief of symptoms and reduce the risk of complications.
- Surgery: In rare cases, surgery may be needed to treat complications such as aneurysms or arterial occlusions.
- Other treatments: Research is underway to use biologic agents such as tocilizumab in the treatment of GCA, particularly in cases where conventional therapy is not effective enough.
Adequate treatment can significantly improve the patient’s quality of life and prevent serious consequences.
List of medications used to treat this disease
Drugs used to treat giant cell arteritis include:
- Prednisone and other corticosteroids.
- Immunosuppressants such as methotrexate and azathioprine.
- Biological agents such as tocilizumab.
- Nonsteroidal anti-inflammatory drugs (NSAIDs).
These drugs can be used either separately or in combination to achieve the best results.
Disease monitoring
Monitoring of giant cell arteritis is performed using:
- Control stages: regular visits to the doctor, allowing to monitor changes in the patient’s condition and the effectiveness of treatment.
- Prognosis: monitoring the dynamics of the disease, the possibility of relapses and complications.
- Complications: risks identified in time, such as loss of vision or cerebrovascular accidents, help to adjust treatment in a timely manner.
It is important to remember that early intervention can significantly reduce the risk of serious consequences.
Age-related features of the disease
Giant cell arteritis is most often observed in elderly patients, while cases are almost never recorded in people under 50. In older patients, symptoms may be more pronounced and develop more quickly, which requires stricter monitoring and treatment.
In the case of a young population, it is important to consider the possibility of rapid progression of the disease in the presence of a predisposition.
Questions and Answers
- What are the main symptoms of giant cell arteritis? The main symptoms include headache, throbbing sensation in the temple area, fatigue, fever and weight loss.
- Who is at risk for developing GCA? At risk are people over 50 years of age, primarily women, as well as people with other inflammatory diseases.
- What diagnostic methods are used to detect GCA? Diagnosis includes assessment of clinical symptoms, laboratory tests (ESR, C-reactive protein) and temporal artery biopsy.
- How is giant cell arteritis treated? Treatment begins with corticosteroids and, in some cases, immunosuppressants and biological agents.
- What is the prognosis for giant cell arteritis? Early treatment can help control symptoms and reduce the risk of complications such as vision loss.
In conclusion, Dr. Oleg Korzhikov advises: "It is important to remain vigilant to the initial symptoms, especially if you are in a risk group. Regular visits to the doctor and following recommendations will help to avoid serious consequences and maintain health for many years."
